Zoetis Inc. (NYSE:ZTS) is one of the best defensive stocks to invest in according to analysts. On July 10, Bank of America ...

Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Zoetis (NYSE:ZTS) added ~7% in the premarket on Tuesday after the animal health company exceeded Street forecasts with its Q2 ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET. Company Participants. Kristin C. Peck - CEO & Director Steven Frank - Vice President of Investor ...

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...

The company raised its full-year 2025 guidance, now expecting revenue between $9.45 billion and $9.6 billion, representing ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging ...